GSK Pharma stock slid 6.7% after Q1 revenue dipped 1.2%, its first drop since March 2023.

• Revenue fell to Rs 8.05 billion due to seasonal disruption, missing expectations per the company statement.
• Stock on track for biggest single-day fall since March 2020, with volume 1.5x the 30-day average.
• Despite Q1 miss, GLAX shares remain up 31% year-to-date, reflecting strong earlier performance.